Personalized Cancer Chemotherapy separately describes and addresses "individualized cancer chemotherapy" (ICC) strategies new and old, to provide readers with new insights into their characteristics and techniques, as well as key debates and future trends in this area. The book devotes chapters to drug sensitivity testing, cancer biomarkers and bioinformatics detection, pharmacogenetics, individualized antimetastatic therapy, drug combinations, assistant chemotherapy, and cost-effectiveness considerations. A major obstacle to controlling cancer growth and metastases in patients is the inappropriate use of anticancer and antimetastatic drugs. Researchers and clinicians are now beginning to focus on ICC also called "personalized cancer chemotherapy" (PCC), to improve therapeutic quality and outcomes by selecting and prescribing the most appropriate and effective drugs. Using genetic, molecular, and bioinformatics data and modern experimental techniques, known tumor genes can be detected more easily than ever before; the average speed of genetic sequencing has increased 15,000 to 50,000 times since the Human Geonme Project was completed. This book will help readers understand the pros and cons of each individualized cancer chemotherapy strategy from different angles so as to make good judgments and predictions of drug responses and clinical outcomes. * Explores the central components of cancer treatment* Investigates new developments in cancer treatment* Discusses the many strategies of individualized cancer chemotherapy
"synopsis" may belong to another edition of this title.
Individualized cancer chemotherapy (ICC) has been designed to meet the requirement of selecting anticancer drugs in clinics and attracting increasing attentions in medical circle and will show more beneficial outcome in the future if we stick on these researches. Personalized Cancer Chemotherapy addresses and reviews this issue by discussing many existing specific strategies of ICC, including drug sensitivity testing, cancer biomarker detections, cancer biomarker-oriented therapy, anticancer drug pharmacogenetics, cancer metastasis therapy, anticancer drug combinations, assistant therapy, mathematics, and computational analysis of cancer malignancy and drug responses, cost effective and finally studies of relationship between different ICC strategies. The relationship between drug response and these techniques or methods is in-depth analyzed, discussed and highlight. Many longstanding key debates and future trends are also intensively discussed, highlighted and debuted with new twists. * Explores the central components of cancer treatment* Investigates new developments in cancer treatment* Discusses the many strategies of individualized cancer chemotherapyAbout the Author:
Dr Da Yong Lu is an associate professor at Shanghai University, PR China studying cancer pathology, biochemistry, pharmacology and clinical therapeutics, especially on the pharmacological studies of new Chinese anticancer agent probimane and MST-16 and antimetastatic targets of fibrinogen and sialic acids and individualized cancer chemotherapy (ICC) and some articles in avian flu, AIDS and neural science. His research interests are focused on the basic studies of cancer biology, pathology, treatment, origins of life and other field of science disciplines. He is as an editorial member of several reputed international journals and has also published more than 50 scientific articles in international journals.
"About this title" may belong to another edition of this title.
Book Description Woodhead Pub Ltd, 2014. Hardcover. Book Condition: Brand New. 1st edition. 84 pages. 9.25x6.25x0.50 inches. In Stock. Bookseller Inventory # __0081003463
Book Description Woodhead Publishing, 2014. Hardback. Book Condition: NEW. 9780081003466 84pp., Hardback, This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. Bookseller Inventory # HTANDREE0890026